Guardant Health (NASDAQ:GH) Shares Up 7.6% – What’s Next?

Guardant Health, Inc. (NASDAQ:GH)’s stock price was up 7.6% during trading on Monday . The company traded as high as $36.57 and last traded at $36.32. Approximately 530,169 shares changed hands during mid-day trading, a decline of 57% from the average daily volume of 1,219,949 shares. The stock had previously closed at $33.76.

Analyst Ratings Changes

GH has been the subject of several research analyst reports. The Goldman Sachs Group raised their price target on Guardant Health from $32.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. boosted their price target on shares of Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Sanford C. Bernstein decreased their target price on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 30th. Finally, Leerink Partners dropped their price target on Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Fifteen analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $40.60.

Guardant Health Trading Up 6.0 %

The company has a debt-to-equity ratio of 16.70, a current ratio of 6.22 and a quick ratio of 5.85. The stock has a market cap of $4.42 billion, a PE ratio of -8.44 and a beta of 1.28. The company’s fifty day moving average is $31.21 and its 200-day moving average is $28.41.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The firm had revenue of $191.48 million during the quarter, compared to analyst estimates of $170.49 million. During the same quarter last year, the company posted ($0.73) EPS. The company’s revenue was up 33.9% on a year-over-year basis. On average, analysts predict that Guardant Health, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Musa Tariq sold 2,320 shares of the firm’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $35.00, for a total value of $81,200.00. Following the transaction, the director now directly owns 2,676 shares of the company’s stock, valued at approximately $93,660. This trade represents a 46.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Meghan V. Joyce sold 2,896 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total transaction of $86,590.40. Following the completion of the sale, the director now owns 7,648 shares of the company’s stock, valued at approximately $228,675.20. The trade was a 27.47 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,432 shares of company stock valued at $175,423. 5.50% of the stock is owned by corporate insiders.

Institutional Trading of Guardant Health

Large investors have recently added to or reduced their stakes in the stock. JNBA Financial Advisors acquired a new position in shares of Guardant Health in the 3rd quarter valued at $26,000. Ashton Thomas Securities LLC purchased a new stake in shares of Guardant Health in the 3rd quarter valued at approximately $34,000. Quarry LP acquired a new position in shares of Guardant Health in the 2nd quarter worth approximately $44,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Guardant Health during the 2nd quarter worth approximately $71,000. Finally, Nisa Investment Advisors LLC increased its holdings in Guardant Health by 168.1% in the 3rd quarter. Nisa Investment Advisors LLC now owns 3,434 shares of the company’s stock valued at $79,000 after purchasing an additional 2,153 shares during the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.